secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2024-01-31T23:59:59+00:00
Accession:  0001193125-24-021084
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte Raises $816.5 Million in Public Offering of Common Stock and Pre-Funded Warrants
--------------------------------------------------------------------------------

- Underwriting agreement with BofA, Jefferies, Leerink, Evercore for 10,937,500 shares at $64.00 per share and 781,250 pre-funded warrants at $63.999 per warrant.
- Pre-funded warrants have an exercise price of $0.001 per share and are exercisable until fully exercised subject to an ownership limitation.
- Underwriters exercised option in full for an additional 1,757,812 shares, bringing total shares offered to 12,695,312.
- Net proceeds expected to be approximately $816.5 million after underwriting discounts and expenses.
- Closing expected on or about February 2, 2024, under effective registration statement on Form S-3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000119312524021084/0001193125-24-021084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000119312524021084/d752729d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-021084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer